The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Intervacc identifies a potential short out-of-stock situation regarding Strangvac
Stockholm, September 20, 2024 – Intervacc AB (publ) predicts that the vaccine Strangvac®, which is approved for sale in Europe and the UK, may be out-of-stock for a short period from the 1st October 2024. The doses of vaccine that are currently available for...Extended Patent Protection for Strangvac approved in the United Kingdom
Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac®, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing...Interim report January – June 2024
The Group in summary 01/04/24 01/04/23 01/01/24 01/01/23 Full year -30/06/24 -30/06/23 -30/06/24 -2023-06-30 2023 Net sales 2 735 1 882 5 129 3 365 8 015 Operating result...Intervacc and the Karolinska Institutet extends contract for the development of innovative animal health vaccines
Stockholm, August 15, 2024 –Intervacc AB (publ) and the Karolinska Institute, KI, announce that they have extended their collaboration to develop a new generation of animal health vaccines using recombinant fusion proteins. The three-year extension means that the...Nyhetstjänster
